Insulet Corporation
- Industry
- Medical Devices
- Exchange
- US
- Country
- USA
- IPO date
- May 15, 2007
- Employees
- 5,400
- Website
- www.insulet.com
Composite valuation range · conservative $110–$120 / fair $120–$160 / optimistic $170–$190. At $145.76, Within the fair intrinsic-value range.
At publication $144.94 (May 31, 2026)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
History
Coming soonThis section is being filled in — check back soon.
Industry position
Coming soonThis section is being filled in — check back soon.
